Angiotensin

Precursor and types

Angiotensinogen

Angiotensinogen is an α-2-globulin synthesized in the liver and is a precursor for angiotensin, but has also been indicated as having many other roles not related to angiotensin peptides. It is a member of the serpin family of proteins, leading to another name: Serpin A8, although it is not known to inhibit other enzymes like most serpins. In addition, a generalized crystal structure can be estimated by examining other proteins of the serpin family, but angiotensinogen has an elongated N-terminus compared to other serpin family proteins. Obtaining actual crystals for X-ray diffractometric analysis is difficult in part due to the variability of glycosylation that angiotensinogen exhibits. The non-glycosylated and fully glycosylated states of angiotensinogen also vary in molecular weight, the former weighing 53 kDa and the latter weighing 75 kDa, with a plethora of partially glycosylated states weighing in between these two values.

Angiotensinogen is also known as renin substrate. It is cleaved at the N-terminus by renin to result in angiotensin I, which will later be modified to become angiotensin II. This peptide is 485 amino acids long, and 10 N-terminus amino acids are cleaved when renin acts on it. The first 12 amino acids are the most important for activity.

:Amino acid sequence: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-...

Plasma angiotensinogen levels are increased by plasma corticosteroid, estrogen, thyroid hormone, and angiotensin II levels. In mice with a full body deficit of angiotensinogen, the effects observed were low newborn survival rate, stunted body weight gain, stunted growth, and abnormal renal development.

Angiotensin I

:Amino acid sequence: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu | Val-Ile-...

Angiotensin I (CAS# 11128-99-7), officially called proangiotensin, is formed by the action of renin on angiotensinogen. Renin cleaves the peptide bond between the leucine (Leu) and valine (Val) residues on angiotensinogen, creating the decapeptide (ten amino acid) (des-Asp) angiotensin I. Renin is produced in the kidneys in response to renal sympathetic activity, decreased intrarenal blood pressure (

Angiotensin I appears to have no direct biological activity and exists solely as a precursor to angiotensin II.

Angiotensin II

:Amino acid sequence: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

Production

Angiotensin I is converted to angiotensin II (AII) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung (but also present in endothelial cells, kidney epithelial cells, and the brain).

Degradation

Angiotensin II is degraded to angiotensin III by angiotensinases located in red blood cells and the vascular beds of most tissues. Angiotensin II has a half-life in circulation of around 30 seconds, whereas, in tissue, it may be as long as 15–30 minutes. Other cleavage products of ACE, seven or nine amino acids long, are also known; they have differential affinity for angiotensin receptors, although their exact role is still unclear.

Physiological effects

Angiotensin II exhibits endocrine, autocrine/paracrine, and intracrine functions.

It promotes aldosterone release from the adrenal cortex, as well as arginine vasopressin release from the posterior pituitary.

It acts directly upon the proximal tubules of the kidney to regulate water and Na+ reabsorption, promoting reabsorption at very low concentrations while increasingly inhibiting reabsorption with increasing concentrations. In the proximal tubule, it promotes Na+ reabsorption and H+ excretion (which is coupled to bicarbonate reabsorption) by the Na+/H+ exchanger.

It causes venous and arterial vasoconstriction by a Gq alpha subunit-coupled receptor upon vascular smooth muscle cells (with downstream IP3-dependent mechanism causing a rise in intracellular Ca2+ to effect smooth muscle excitation-contraction coupling), thus acting to increase blood pressure.

Pharmacological significance

ACE is a pharmaceutical target of ACE inhibitor drugs, which decrease the rate of conversion of angiotensin I to angiotensin II, and of angiotensin II receptor antagonists which block angiotensin II AT1 receptors.

Angiotensin II results in increased inotropy, chronotropy, catecholamine and sensitivity, aldosterone levels, vasopressin levels, and cardiac remodeling and vasoconstriction through AT1 receptors on peripheral vessels (conversely, AT2 receptors impair cardiac remodeling). This is why ACE inhibitors and ARBs help to prevent remodeling that occurs secondary to angiotensin II and are beneficial in congestive heart failure.

Angiotensin III

:Amino acid sequence: Asp | Arg-Val-Tyr-Ile-His-Pro-Phe

Angiotensin III, along with angiotensin II, is considered an active peptide derived from angiotensinogen. It is formed by removing an amino acid from angiotensin II by glutamyl aminopeptidase A, which cleaves the N-terminal Asp residue.

Angiotensin III has 40% of the pressor activity of angiotensin II, but 100% of the aldosterone-producing activity. It increases mean arterial pressure.

Activation of the AT2 receptor by angiotensin III triggers natriuresis, while AT2 activation via angiotensin II does not. This natriuretic response via angiotensin III occurs when the AT1 receptor is blocked.

Angiotensin IV

:Amino acid sequence: Arg | Val-Tyr-Ile-His-Pro-Phe

Angiotensin IV is a hexapeptide that, like angiotensin III, has some lesser activity. Angiotensin IV has a wide range of activities in the central nervous system.

The exact identity of AT4 receptors has not been established. There is evidence that the AT4 receptor is insulin-regulated aminopeptidase (IRAP). There is also evidence that angiotensin IV interacts with the HGF system through the c-Met receptor.

Synthetic small molecule analogues of angiotensin IV with the ability to penetrate through blood brain barrier have been developed.

The AT4 site may be involved in memory acquisition and recall, as well as blood flow regulation. Angiotensin IV and its analogs may also benefit spatial memory tasks such as object recognition and avoidance (conditioned and passive avoidance). Studies have also shown that the usual biological effects of angiotensin IV on the body are not affected by common AT2 receptor antagonists such as the hypertension medication losartan.

Effects ==

:See also Renin–angiotensin system#Effects Angiotensins II, III and IV have a number of effects throughout the body:

Adipic

Angiotensins "modulate fat mass expansion through upregulation of adipose tissue lipogenesis ... and downregulation of lipolysis."

Cardiovascular

Angiotensins are potent direct vasoconstrictors, constricting arteries and increasing blood pressure. This effect is achieved through activation of the GPCR AT1, which signals through a Gq protein to activate phospholipase C, and subsequently increase intracellular calcium.

Angiotensin II has prothrombotic potential through adhesion and aggregation of platelets and stimulation of PAI-1 and PAI-2.

Neural

Angiotensin II increases thirst sensation (dipsogen) through the area postrema and subfornical organ of the brain, decreases the response of the baroreceptor reflex, increases the desire for salt, increases secretion of ADH from the posterior pituitary, and increases secretion of ACTH from the anterior pituitary.

Adrenal

Angiotensin II acts on the adrenal cortex, causing it to release aldosterone, a hormone that causes the kidneys to retain sodium and lose potassium. Elevated plasma angiotensin II levels are responsible for the elevated aldosterone levels present during the luteal phase of the menstrual cycle.

Renal

Angiotensin II has a direct effect on the proximal tubules to increase Na+ reabsorption. It has a complex and variable effect on glomerular filtration and renal blood flow depending on the setting. Increases in systemic blood pressure will maintain renal perfusion pressure; however, constriction of the afferent and efferent glomerular arterioles will tend to restrict renal blood flow. The effect on the efferent arteriolar resistance is, however, markedly greater, in part due to its smaller basal diameter; this tends to increase glomerular capillary hydrostatic pressure and maintain glomerular filtration rate. A number of other mechanisms can affect renal blood flow and GFR. High concentrations of Angiotensin II can constrict the glomerular mesangium, reducing the area for glomerular filtration. Angiotensin II is a sensitizer to tubuloglomerular feedback, preventing an excessive rise in GFR. Angiotensin II causes the local release of prostaglandins, which, in turn, antagonize renal vasoconstriction. The net effect of these competing mechanisms on glomerular filtration will vary with the physiological and pharmacological environment.

References

References

1. (April 1958). "An Interpretive Review of the Conference Proceedings". Circulation.
2. (December 2001). "History about the discovery of the renin-angiotensin system". Hypertension.
3. "Angiotensin {{!}} Hormone Health Network".
4. (July 2016). "Structure and functions of angiotensinogen". Hypertension Research.
5. "AGT - Angiotensinogen precursor - Homo sapiens (Human) - AGT gene & protein".
6. (October 1998). "Angiotensinogen cleavage by renin: importance of a structurally constrained N-terminus". FEBS Letters.
7. (October 1998). "Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents". JAMA.
8. (2008). "Harrison's principles of internal medicine". McGraw-Hill Medical.
9. (1987). "Direct demonstration of macula densa-mediated renin secretion". Science.
10. (November 1978). "Importance of chloride for acute inhibition of renin by sodium chloride". The American Journal of Physiology.
11. (May 2006). "Adenosine as a mediator of macula densa-dependent inhibition of renin secretion". American Journal of Physiology. Renal Physiology.
12. (2013). "Seldin and Giebisch's the Kidney". Academic Press.
13. (2023). "StatPearls". StatPearls Publishing.
14. (1996). "Comprehensive Human Physiology: From Cellular Mechanisms to Integration". Springer.
15. (2012). "First Aid for the Basic Sciences. Organ Systems". McGraw-Hill.
16. (2012). "Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension". International Journal of Hypertension.
17. "Angiotensin III". NIH.
18. (March 2006). "Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat". Hypertension.
19. (November 2004). "The angiotensin IV/AT4 receptor". Cellular and Molecular Life Sciences.
20. (December 2008). "Cognitive-enhancing effects of angiotensin IV". BMC Neuroscience.
21. (December 2001). "Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase". The Journal of Biological Chemistry.
22. (2015-01-01). "The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease". Journal of Alzheimer's Disease.
23. (February 2015). "The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases". Progress in Neurobiology.
24. (January 1995). "The angiotensin IV system: functional implications". Frontiers in Neuroendocrinology.
25. (September 2018). "Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies". Neuroscience and Biobehavioral Reviews.
26. (January 2011). "Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity". Kidney International.
27. (November 2003). "Cellular mechanism of vasoconstriction induced by angiotensin II: it remains to be determined". Circulation Research.
28. (May 2001). "Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture". Hypertension.
29. (August 1999). "Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells". Kidney International.
30. (May 1993). "Sensory circumventricular organs and brain homeostatic pathways". FASEB Journal.
31. (December 1989). "High metabolic activity in the dorsal vagal complex of Brattleboro rats". Brain Research.
32. (March 1990). "Metabolic activation of efferent pathways from the rat area postrema". The American Journal of Physiology.
33. (2019). "Ganong's review of medical physiology". McGraw-Hill Education.
34. (2005). "Medical Physiology: a Cellular and Molecular Approach". Elsevier Saunders.